UCFA
ZVRA icon

United Capital Financial Advisors’s Zevra Therapeutics ZVRA Stock Holding History

United Capital Financial Advisors’s Portfolio ZVRA Stock Details ZVRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-890
Closed -$93K – 1382
2018
Q2 		$93K Buy
+890
New +$86.9K ﹤0.01% 1276

Other funds holding ZVRA

DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
AWA
Arete Wealth Advisors Chicago, Illinois $1.33B AUM 25.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

United Capital Financial Advisors's ZVRA Position: Q3 2018 in Review

United Capital Financial Advisors sold out of Zevra Therapeutics (ZVRA) in Q3 2018, closing a stake of 890 shares — an estimated $93K sold.

United Capital Financial Advisors first reported a position in ZVRA in Q2 2018 and held it in 1 quarter. The position peaked at $93K in Q2 2018. 33 funds tracked by Wall St. Rank hold ZVRA as of Q3 2018.

  • United Capital Financial Advisors reported no remaining Zevra Therapeutics position as of Q3 2018 after selling out during the quarter.
  • United Capital Financial Advisors sold 890 Zevra Therapeutics shares in Q3 2018, an estimated $93K.
  • United Capital Financial Advisors first reported a position in Zevra Therapeutics in Q2 2018 and held it in 1 quarter.
  • United Capital Financial Advisors's Zevra Therapeutics position peaked at $93K in Q2 2018.
  • 33 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2018.

Based on United Capital Financial Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.